UBS upgrades Monte Rosa Therapeutics stock to Hold while trials advance

Published on 10/16/2026 at 01:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GFORCE-1 enrolled 108 subjects and cut hsCRP 85 percent on October 1, 2026. Monte Rosa Therapeutics stock targets Phase 2 in Q4 2026.

Pipeline and analyst view

UBS moved its Monte Rosa Therapeutics rating to Hold on October 14, 2026.
GFORCE-1 enrolled 108 subjects and produced an 85 percent median hsCRP reduction on October 1, 2026.
MarketBeat cited a USD 26.67 average analyst target on October 14, 2026.

GLUE, US61225M1027, Illustration mit AI erstellt.

Monte Rosa Therapeutics (ISIN US61225M1027) was upgraded to Hold by UBS Group on October 14, 2026, according to MarketBeat. The rating change leaves the biotechnology company between a fresh clinical catalyst and a demanding financial profile.

Three milestones shape the story

On September 8, 2026, Monte Rosa reported a milestone tied to the start of a Phase 2 study for VAV1-directed MRT-6160, according to StockTitan. On October 1, 2026, the company said its GFORCE-1 Phase 1 study of MRT-8102 enrolled 108 subjects and delivered median hsCRP reductions of 85 percent, according to the Monte Rosa Therapeutics release. On October 14, 2026, UBS moved its rating to Hold, while MarketBeat cited a USD 26.67 average analyst target.

What does the trial mean for risk?

The Phase 1 result is a biomarker signal rather than proof of clinical benefit. Monte Rosa said MRT-8102 produced 80 to 90 percent median NEK7 degradation across the tested doses, and treatment-emergent adverse events affected 33 percent of treated participants versus 30 percent for placebo, according to the company release.

The financial backdrop is less supportive. For the second quarter of 2026, revenue was USD 8.97 million, while the GAAP net loss reached USD 43.40 million. The quarter also produced diluted GAAP earnings per share of minus USD 0.43, compared with a consensus estimate of minus USD 0.38, according to MarketBeat. Market capitalization stood at USD 863.4 million on October 15, 2026.

Next clinical dates carry the focus

Monte Rosa's next stated development windows are Q4 2026 or Q1 2027 for gout testing, followed by H1 2027 studies in coronary artery disease and hidradenitis suppurativa, according to StockTitan. The company also granted inducement awards covering 86,725 options and 19,150 restricted stock units effective October 1, 2026, adding a concrete hiring milestone to the chronology.

Pipeline facts frame the valuation

Monte Rosa is a clinical-stage biotechnology company developing molecular glue degrader medicines across oncology, autoimmune, inflammatory, cardiovascular and cardiometabolic diseases. Its Nasdaq listing uses the ticker GLUE, and its primary operating base is Boston.